Vir Biotechnology (VIR) FCF Margin (2018 - 2026)
Vir Biotechnology recorded quarterly FCF Margin of 457848.28% in Q1 2026, down 1118506.58% quarter-over-quarter from 40.93% in Q4 2025, and down 45521816.0% year-over-year from N/an in Q1 2025.
Vir Biotechnology's FCF Margin history runs 9 years deep, the most recent figure standing at 457848.28% for Q1 2026.
- In Q1 2026, FCF Margin fell 45521816.0% year-over-year to 457848.28%; the TTM figure through Mar 2026 stood at 685.92% (up 133764.0% YoY), while the FY2025 annual figure was 578.52%, up 3283.0% from the prior year.
- FCF Margin came in at 457848.28% for Q1 2026 at Vir Biotechnology, down from 40.93% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 2312.48% in Q2 2022 to a low of 457848.28% in Q1 2026.
- A 5-year average of 33316.42% and a median of 724.34% in 2024 frame the typical range for FCF Margin.
- Across the five-year window, FCF Margin surged 794723 bps in 2024 and plunged 45521816 bps in 2026, its largest moves.
- Vir Biotechnology's FCF Margin stood at 45.64% in 2022, then slumped by 1529 bps to 652.06% in 2023, then fell by 11 bps to 724.34% in 2024, then surged by 94 bps to 40.93% in 2025, then tumbled by 1118507 bps to 457848.28% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 457848.28%, 40.93%, and 69952.92% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -3.98% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 43.35% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 23.53% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.17% |
| 10 | Vir Biotechnology | 1.33 Bn | 1.33 Bn | - | -457,848.28% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -457,848.28% |
| Dec 31, 2025 | -40.93% |
| Sep 30, 2025 | -69,952.92% |
| Jun 30, 2025 | -10,111.78% |
| Mar 31, 2025 | -2,630.11% |
| Dec 31, 2024 | -724.34% |
| Sep 30, 2024 | -7,321.34% |
| Jun 30, 2024 | -2,553.27% |
| Mar 31, 2024 | -215.21% |
| Dec 31, 2023 | -652.06% |
| Sep 30, 2023 | -6,045.59% |
| Jun 30, 2023 | -10,500.50% |
| Mar 31, 2023 | -210.70% |
| Dec 31, 2022 | 45.64% |
| Sep 30, 2022 | 26.41% |
| Jun 30, 2022 | 2,312.48% |
| Mar 31, 2022 | 43.35% |
| Dec 31, 2021 | -0.66% |
| Sep 30, 2021 | -108.17% |
| Jun 30, 2021 | 81.97% |
| Mar 31, 2021 | -4,549.95% |
| Dec 31, 2020 | -4,872.09% |
| Sep 30, 2020 | -2,661.57% |
| Jun 30, 2020 | -29.48% |
| Mar 31, 2020 | -855.72% |
| Dec 31, 2019 | -4,038.47% |
| Sep 30, 2019 | -2,211.26% |
| Jun 30, 2019 | -1,316.95% |
| Mar 31, 2019 | -900.44% |
| Dec 31, 2018 | -1,193.95% |